JPRN-UMIN000023108招募中3 期
A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab (JCOG1308C, RE-GEND-pIII) - A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab (JCOG1308C, RE-GEND-pIII)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 210 人开始时间: 2016年7月11日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Body temperature >= 38 degrees Celsius at registration 4) Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding 5) Psychosis or with psychotic symptom 6) Continuous systemic use of immunosuppressant except for steroid 7) Uncontrolled diabetes mellitus or routine administration of insulin 8) Unstable angina within 3 weeks, with a history of myocardial infarction within 6 months, or New York Heart Association (NYHA) class II or greater congestive heart failure 9) Inadequately controlled hypertension (cannot be controlled to a systolic pressure of >= 150 mmHg and a diastolic pressure of >= 100 mmHg) 10) History of symptomatic cerebrovascular disorder (including subarachnoid hemorrhage, cerebral infarction and transient ischemic attack) within 6 months or history of vascular disorder requiring intervention (including venous/arterial thrombosis or embolism and aortic aneurysm) within 6 moths 11) History of grade >= 2 hemoptysis within 28 days 12) History of hemorrhagic tendency (e.g., coagulation disorder) or any grade >= 3 hemorrhage within 28 days 13) History of gastrointestinal perforation, fistula, abdominal abscess or uncontrolled peptic ulcer within 6 months 14) Interstitial pneumonia, pulmonary fibrosis, or severe lung emphysema 15) Severe non-healing wound or traumatic fracture at enrolment 16) Hypersensitivity to CHO-derived drugs or other recombinant antibodies 17) Gadolinium allergy 18) Positive HIV antibody 19) Positive HBs antigen
研究者
相似试验
进行中（未招募）
1 期
A Phase III multicenter, randomized study with lenalidomide (Revlimid) maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: MCL0208 - IIL-MCL0208Mantle cell lymphomaMedDRA version: 12.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2009-012807-25-PTIIL INTERGRUPPO ITALIANO LINFOMI ONLUS250
进行中（未招募）
不适用
A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intensive and high-dose chemo-immunotherapy with autologus pheripherical staminal cells. - IIL/DLCL04EUCTR2007-000275-42-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS376
进行中（未招募）
不适用
A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first lineEUCTR2012-004362-17-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE'400
进行中（未招募）
1 期
A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first linePlatinum sensitive ovarian cancer patients progressing or recurring after a first-line treatment including bevacizumab.MedDRA version: 17.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004362-17-GRISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE'400
进行中（未招募）
1 期
A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first lineplatinum sensitive ovarian cancer patients progressing or recurring after a first-line treatment including bevacizumab.MedDRA version: 18.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004362-17-BEISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE'400